Data from Pharmawand - Curated by EPG Health - Date added 30 December 2018

Adamis Pharmaceuticals Corporation has announced the submission of a New Drug Application (NDA) to the FDA for its fast-dissolving sublingual tadalafil tablet. This product candidate is designed for the treatment of erectile dysfunction. Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.

Adamis has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil with its first goal to demonstrate comparability to Cialis and additional benefits of a rapidly acting sublingual formulation.

Comment: If approved, APC-8000 will be a fast-disintegrating sublingual tablet containing tadalafil to treat erectile dysfunction.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Load more

Related Content